KYKathleen Y. Yang

Kathleen Y. Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathleen Y. Yang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Psychometric evaluation of the NFOSI-18 disease related symptoms – Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004

    by Xiaodan Tang, Helen Huang, John D. Peipert, Anne Zola, Joseph Buscema, Kathleen Yang, William Tew, Roisin E. O'CEarbhaill, Carolyn Muller, Michael J. Goodheart, et al.

  • Abnormal Pap Smear and Cervical Cancer in Pregnancy

    by Kathleen Y. Yang

    Pregnancy represents a unique opportunity to screen reproductive age women for cervical cancer and abnormal cervical cytology is relatively common in this population. In the absence of large, prospective clinical trials investigating the optimal management strategies for cervical dysplasia in pregnant women, consensus guidelines established by the American Society for Colposcopy and Cervical Pathology is available with considerations to this special patient population. Modalities for evaluation and management algorithms are reviewed and summarized from largely case series of pregnant women with cervical dysplasia and cervical cancer.


  • A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families

    by Kathleen Y. Yang, Aaron B. Caughey, Sarah E. Little, Michael K. Cheung, Lee-May Chen

    Women at risk for Lynch Syndrome/HNPCC have an increased lifetime risk of endometrial and ovarian cancer. This study investigates the cost-effectiveness of prophylactic surgery versus surveillance in women with Lynch Syndrome. A decision analytic model was designed incorporating key clinical decisions and existing probabilities, costs, and outcomes from the literature. Clinical forum where risk-reducing surgery and surveillance were considered. A theoretical population of women with Lynch Syndrome at age 30 was used for the analysis. A decision analytic model was designed comparing the health outcomes of prophylactic hysterectomy with bilateral salpingo-oophorectomy at age 30 versus annual gynecologic screening versus annual gynecologic exam. The literature was searched for probabilities of different health outcomes, results of screening modalities, and costs of cancer diagnosis and treatment. Cost-effectiveness expressed in dollars per discounted life-years. Risk-reducing surgery is the least expensive option, costing $23,422 per patient for 25.71 quality-adjusted life-years (QALYs). Annual screening costs $68,392 for 25.17 QALYs; and annual examination without screening costs $100,484 for 24.60 QALYs. Further, because risk-reducing surgery leads to both the lowest costs and the highest number of QALYs, it is a dominant strategy. Risk-reducing surgery is the most cost-effective option from a societal healthcare cost perspective.


  • Gynecologic Cancer Prevention in Lynch Syndrome/Hereditary Nonpolyposis Colorectal Cancer Families

    by Lee-May Chen, Kathleen Y. Yang, Sarah E. Little, Michael K. Cheung, Aaron B. Caughey

    Women carrying a Lynch syndrome/hereditary nonpolyposis colorectal cancer (HNPCC) germline mutation have an estimated 40% to 60% lifetime risk of developing endometrial cancer and a 10% to 12% risk of ovarian cancer. The incidence of gynecological cancer in these women is at least as great as that of colorectal cancer and possibly greater. The median age of incidence is in the fourth decade with a trend toward earlier stage and grade, but one-fourth of affected women present with high-risk features that warrant adjuvant therapy. Current practice is to identify women from high-risk families so that genetic testing may be considered. It remains unclear whether high-risk women should be followed or undergo prophylactic surgery. The investigators developed a decision analytic model with which to compare management strategies for women carrying a Lynch/HNPCC mutation. Three approaches were analyzed: lifetime annual gynecological examinations; annual screening by transvaginal ultrasonography, endometrial biopsy, and serum CA-125 testing; and prophylactic hysterectomy with bilateral salpingo-oophorectomy at age 30 years. Relevant studies were reviewed, and cancer mortality outcomes were estimated from the Surveillance, Epidemiology, and End Results database for the years 1988–2001. In the surgical arm, 0.0056% of women were diagnosed with ovarian cancer and 0.0060% with endometrial cancer. The numbers increased to 3.7% and 18.4%, respectively, in women who were screened annually and who had surgery if screen-positive, and to 8.3% and 48.7% in those having annual examinations and were diagnosed with interval cancers. Surgery was associated with the longest expected survival time, 80 years, followed by screening at 79 years and annual examinations at 77 years. Surgery still yielded the most expected life years when starting at age 30 and discounting life years at 3%. Comparing prophylactic surgery with screening, 75 surgeries would be needed to save one woman's entire life. In contrast, only 28 preventive surgeries would be needed to prevent 1 case of ovarian cancer, and 6 to prevent 1 case of endometrial cancer. This analysis suggests that prophylactic hysterectomy with bilateral salpingo-oophorectomy is an effective approach to preventing gynecological cancers in Lynch/HNPCC women.